Pathway activation patterns in diffuse large B-cell lymphomas

被引:31
作者
Bentink, S.
Wessendorf, S.
Schwaenen, C.
Rosolowski, M. [2 ]
Klapper, W. [3 ]
Rosenwald, A. [4 ]
Ott, G. [4 ,12 ]
Banham, A. H. [5 ]
Berger, H. [2 ]
Feller, A. C. [6 ]
Hansmann, M-L [7 ]
Hasenclever, D. [2 ]
Hummel, M. [8 ]
Lenze, D. [8 ]
Moeller, P. [9 ]
Stuerzenhofecker, B. [10 ]
Loeffler, M. [2 ]
Truemper, L. [10 ]
Stein, H. [8 ]
Siebert, R. [11 ]
Spang, R. [1 ]
机构
[1] Univ Regensburg, Computat Diagnost Grp, Inst Funct Genom, D-93053 Regensburg, Germany
[2] Univ Leipzig, Inst Med Informat Stat & Epidemiol, Leipzig, Germany
[3] Univ Kiel, Inst Hematopathol, Univ Hosp Schleswig Holstein, Kiel, Germany
[4] Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany
[5] Univ Oxford, Nuffield Dept Clin Lab Sci, Oxford, England
[6] Univ Hosp Schleswig Holstein, Inst Pathol, Lubeck, Germany
[7] Univ Hosp Frankfurt, Inst Pathol, Frankfurt, Germany
[8] Charite, Inst Pathol, D-13353 Berlin, Germany
[9] Univ Hosp Ulm, Inst Pathol, Ulm, Germany
[10] Univ Gottingen, Dept Hematol & Oncol, Gottingen, Germany
[11] Univ Kiel, Dept Human Genet, Univ Hosp Schleswig Holstein, Kiel, Germany
[12] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany
关键词
lymphoma; oncogenic pathways; transcriptional modules; cancer;
D O I
10.1038/leu.2008.166
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Deregulation of cell signaling pathways controlling cell growth and cell survival is a common feature of all cancers. Although a core repertoire of oncogenic mechanisms is widely conserved between various malignancies, the constellation of pathway activities can vary even in patients with the same malignant disease. Modern molecularly targeted cancer drugs intervene in cell signaling compensating for pathway deregulation. Hence characterizing tumors with respect to pathway activation will become crucial for treatment decisions. Here we have used semi-supervised machine learning methodology to generate signatures of eight oncogene-inducible pathways, which are conserved across epithelial and lymphoid tissues. We combined them to patterns of pathway activity called PAPs for pathway activation patterns and searched for them in 220 morphologically, immunohistochemically and genetically well-characterized mature aggressive B-cell lymphomas including 134 cases with clinical data available. Besides Burkitt lymphoma, which was characterized by a unique pattern, the PAPs identified four distinct groups of mature aggressive B-cell lymphomas across independent gene expression studies with distinct biological characteristics, genetic aberrations and prognosis. We confirmed our findings through cross-platform analysis in an independent data set of 303 mature aggressive B-cell lymphomas.
引用
收藏
页码:1746 / 1754
页数:9
相关论文
共 24 条
[21]  
von Heydebreck A, 2001, Bioinformatics, V17 Suppl 1, pS107
[22]   Predicting the clinical status of human breast cancer by using gene expression profiles [J].
West, M ;
Blanchette, C ;
Dressman, H ;
Huang, E ;
Ishida, S ;
Spang, R ;
Zuzan, H ;
Olson, JA ;
Marks, JR ;
Nevins, JR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11462-11467
[23]   FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations [J].
Wlodarska, I ;
Veyt, E ;
De Paepe, P ;
Vandenberghe, P ;
Nooijen, P ;
Theate, I ;
Michaux, L ;
Sagaert, X ;
Marynen, P ;
Hagemeijer, A ;
De Wolf- Peeters, C .
LEUKEMIA, 2005, 19 (08) :1299-1305
[24]   A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma [J].
Wright, G ;
Tan, B ;
Rosenwald, A ;
Hurt, EH ;
Wiestner, A ;
Staudt, LM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (17) :9991-9996